Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
- PMID: 23579075
- DOI: 10.1016/j.coi.2013.02.009
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Abstract
For tumor antigen-specific T cells to effectively control the growth of cancer cells in vivo, they must gain access to, and function within, the tumor microenvironment. While tumor antigen-based vaccines and T cell adoptive transfer strategies can result in clinical benefit in a subset of patients, most of the patients do not respond clinically. Even for tumor-infiltrating lymphocyte (TIL)-based adoptive transfer for patients with metastatic melanoma, which can provide tumor shrinkage in around 50% of treated individuals, many patients are not eligible, in part because there are not sufficient TIL present in the resected tumor. Thus, the denominator is in fact larger, and it has been suggested that absence of TIL may be a marker for poor efficacy of immunotherapies in general. While qualitative and/or quantitative features of the T cells are important considerations for efficacy, a major component of primary resistance likely can be attributed to the tumor microenvironment. Data are accumulating suggesting that two major categories of immune resistance within the tumor microenvironment may exist: failure of T cell trafficking due to low levels of inflammation and lack of chemokines for migration, and dominant suppression through immune inhibitory mechanisms. New therapeutic interventions are being guided by these observations, and preliminary clinical success is validating this working model.
Copyright © 2013. Published by Elsevier Ltd.
Similar articles
-
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.Semin Oncol. 2015 Aug;42(4):663-71. doi: 10.1053/j.seminoncol.2015.05.011. Epub 2015 Jun 3. Semin Oncol. 2015. PMID: 26320069 Free PMC article. Review.
-
Trafficking of T cells into tumors.Cancer Res. 2014 Dec 15;74(24):7168-74. doi: 10.1158/0008-5472.CAN-14-2458. Epub 2014 Dec 4. Cancer Res. 2014. PMID: 25477332 Review.
-
The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials.Cancer Detect Prev. 1994;18(1):43-50. Cancer Detect Prev. 1994. PMID: 8162605 Review.
-
Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells.Immunol Invest. 2014;43(6):517-34. doi: 10.3109/08820139.2013.857352. Epub 2013 Dec 2. Immunol Invest. 2014. PMID: 24295450 Review.
-
The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.Annu Rev Med. 1996;47:481-91. doi: 10.1146/annurev.med.47.1.481. Annu Rev Med. 1996. PMID: 8712798 Review.
Cited by
-
HSPD1 Supports Osteosarcoma Progression through Stabilizing ATP5A1 and thus Activation of AKT/mTOR Signaling.Int J Biol Sci. 2024 Sep 23;20(13):5162-5190. doi: 10.7150/ijbs.100015. eCollection 2024. Int J Biol Sci. 2024. PMID: 39430254 Free PMC article.
-
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy.Biomedicines. 2024 Sep 23;12(9):2158. doi: 10.3390/biomedicines12092158. Biomedicines. 2024. PMID: 39335671 Free PMC article. Review.
-
Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals MMP mediated expression patterns by distinct tumor microenvironment immune profiles in cervical cancer.J Cancer. 2024 Aug 13;15(16):5258-5276. doi: 10.7150/jca.96429. eCollection 2024. J Cancer. 2024. PMID: 39247608 Free PMC article.
-
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.medRxiv [Preprint]. 2024 Jul 21:2024.07.19.24310726. doi: 10.1101/2024.07.19.24310726. medRxiv. 2024. PMID: 39072034 Free PMC article. Preprint.
-
T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin.Acta Pharmacol Sin. 2024 Oct;45(10):2186-2198. doi: 10.1038/s41401-024-01316-6. Epub 2024 Jun 10. Acta Pharmacol Sin. 2024. PMID: 38858494
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources